{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:02:19Z","timestamp":1774080139915,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The prognosis of patients with anaplastic thyroid cancer (ATC) remains dismal. A small portion of patients experience longterm survival and need to be identified before treatment allocation. Survival scores may guide clinicians making more informed decisions about treatment options and improve the understanding of patients\u2019 prognosis. The aim of this study was to validate two prognostic scores using an independent dataset to analyze which prognostic index is superior in discriminating survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Thirty-four patients with histologically confirmed ATC diagnosed between January 2009 and December 2019 were consecutively treated at our department and evaluated. Next generation sequencing was performed in 7 (21%) patients, but no druggable mutation was found. 50% of all patients received surgery and 56% were treated with chemoradiotherapy. The median radiation dose in equivalent dose in 2\u00a0Gy fractions (EQD2) was 50\u00a0Gy (SD:21\u00a0Gy). The study compared the discrimination of the Sugitani Prognostic Index (SPI) and the Marchand-Crety Prognostic Score (MCPS) using concordance statistics, area under the receiver-operating characteristics curve (AUC), net reclassification index, and integrated discrimination improvement for 6-month survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median survival of the entire cohort was 5 months (range: 1-133). The AUC for 6-month survival was 0.85 (95% confidence interval [CI]:0.72\u20130.97) for SPI and 0.69 (95% CI: 0.56\u20130.83) for MCPS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Using the net reclassification index (NRI), 73% of patients were correctly reclassified using SPI instead of MCPS for 6-month survival (<jats:italic>p<\/jats:italic>\u2009=\u20090.0237).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The SPI was more accurate than the MCPS to determine patients\u2019 life expectancies and should be recommended for clinical guidance and treatment allocation. In the last decade, comprehensive genetic profiling of actionable mutations in ATC has become vital to guide targeted therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-13217-2","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T10:13:26Z","timestamp":1732875206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of two predictive models for survival in anaplastic thyroid cancer (ATC)"],"prefix":"10.1186","volume":"24","author":[{"given":"Lukas","family":"K\u00e4smann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Rennollet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Gurtner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Oliinyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria Florentine","family":"Koehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Neu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Spitzweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefine","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"13217_CR1","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1089\/thy.2012.0302","volume":"22","author":"RC Smallridge","year":"2012","unstructured":"Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association Guidelines for Management of patients with anaplastic thyroid Cancer. Thyroid. 2012;22:1104\u201339.","journal-title":"Thyroid"},{"key":"13217_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/542358","volume":"2011","author":"G Nagaiah","year":"2011","unstructured":"Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid Cancer: a review of Epidemiology, Pathogenesis, and treatment. J Oncol. 2011;2011:1\u201313.","journal-title":"J Oncol"},{"key":"13217_CR3","doi-asserted-by":"publisher","first-page":"461","DOI":"10.21873\/invivo.12279","volume":"35","author":"T Augustin","year":"2021","unstructured":"Augustin T, Oliinyk D, Rauch J, Koehler VF, Spitzweg C, Belka C, et al. Radiation to the primary tumor in metastatic anaplastic thyroid cancer. vivo. 2021;35:461\u20135.","journal-title":"vivo"},{"key":"13217_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1089\/thy.2020.0086","volume":"30","author":"B Xu","year":"2020","unstructured":"Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, et al. Dissecting anaplastic thyroid carcinoma: a Comprehensive Clinical, histologic, immunophenotypic, and Molecular Study of 360 cases. Thyroid. 2020;30:1505\u201317.","journal-title":"Thyroid"},{"key":"13217_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, et al. 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid. 2021;31:337\u201386.","journal-title":"Thyroid"},{"key":"13217_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"13217_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion\u2013positive cancers in adults and children. N Engl J Med. 2018;378:731\u20139.","journal-title":"N Engl J Med"},{"key":"13217_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382.","journal-title":"Lancet Oncol"},{"key":"13217_CR9","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours.\u00a0Hoboken, NJ: John Wiley & Sons; 2017. ISBN: 978-1-119-26356-2.","DOI":"10.1002\/9780471420194.tnmc23.pub3"},{"key":"13217_CR10","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.21037\/tcr-20-1364","volume":"9","author":"H Lee","year":"2020","unstructured":"Lee H, Kim SY, Kim S-M, Chang H-J, Lee YS, Park CS, et al. Long-term survival of patients with anaplastic thyroid cancer after multimodal treatment. Translational Cancer Res. 2020;9:5430.","journal-title":"Translational Cancer Res"},{"key":"13217_CR11","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.3390\/jcm9103231","volume":"9","author":"T Augustin","year":"2020","unstructured":"Augustin T, Oliinyk D, Koehler VF, Rauch J, Belka C, Spitzweg C, et al. Clinical outcome and toxicity in the treatment of anaplastic thyroid cancer in elderly patients. J Clin Med. 2020;9:3231.","journal-title":"J Clin Med"},{"key":"13217_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1856\u201383.","journal-title":"Ann Oncol"},{"key":"13217_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol. 2020;6:1397.","journal-title":"JAMA Oncol"},{"key":"13217_CR14","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8470","author":"C Romei","year":"2018","unstructured":"Romei C, Tacito A, Molinaro E, Piaggi P, Cappagli V, Pieruzzi L, et al. Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: a single institute experience. Oncol Lett. 2018. https:\/\/doi.org\/10.3892\/ol.2018.8470.","journal-title":"Oncol Lett"},{"key":"13217_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2016.0254","volume":"27","author":"B Bonhomme","year":"2017","unstructured":"Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleann\u00e9e G, et al. Molecular Pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases. Thyroid. 2017;27:682\u201392.","journal-title":"Thyroid"},{"key":"13217_CR16","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","volume":"10","author":"S-K Yoo","year":"2019","unstructured":"Yoo S-K, Song YS, Lee EK, Hwang J, Kim HH, Jung G, et al. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer. Nat Commun. 2019;10:2764.","journal-title":"Nat Commun"},{"key":"13217_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s002680020166","volume":"25","author":"I Sugitani","year":"2001","unstructured":"Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg. 2001;25:617\u201322.","journal-title":"World J Surg"},{"issue":"3","key":"13217_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.21873\/anticanres.14915","volume":"41","author":"C Marchand-Crety","year":"2021","unstructured":"Marchand-Crety C, Pascard M, Debreuve-Theresette A, Ettalhaoui L, Schvartz C, Zalzali M, Brugel M, Bellefqih S, Servagi-Vernat S. Prognostic factors and survival score for patients with anaplastic thyroid carcinoma: a retrospective study from a regional registry. Anticancer Res. 2021;41(3):1555\u201361.","journal-title":"Anticancer Res"},{"key":"13217_CR19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cncr.32548","volume":"126","author":"D Fan","year":"2020","unstructured":"Fan D, Ma J, Bell AC, Groen AH, Olsen KS, Lok BH, et al. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer. 2020;126:444\u201352.","journal-title":"Cancer"},{"key":"13217_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-023-02249-w","volume":"18","author":"J Jacob","year":"2023","unstructured":"Jacob J, Vordermark D, Lorenz K, Medenwald D. Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years. Radiat Oncol. 2023;18:1\u201311.","journal-title":"Radiat Oncol"},{"key":"13217_CR21","doi-asserted-by":"publisher","first-page":"704596","DOI":"10.3389\/fendo.2021.704596","volume":"12","author":"N Kong","year":"2021","unstructured":"Kong N, Xu Q, Zhang Z, Cui A, Tan S, Bai N. Age influences the prognosis of anaplastic thyroid cancer patients. Front Endocrinol. 2021;12:704596.","journal-title":"Front Endocrinol"},{"key":"13217_CR22","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.21873\/anticanres.11023","volume":"36","author":"L K\u00e4smann","year":"2016","unstructured":"K\u00e4smann L, Bolm L, Janssen S, Rades D. Prognostic factors for survival in patients treated with multimodal therapy for anaplastic thyroid cancer. Anticancer Res. 2016;36:4697\u2013700.","journal-title":"Anticancer Res"},{"key":"13217_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1272\/jnms.2018_85-3","volume":"85","author":"I Sugitani","year":"2018","unstructured":"Sugitani I, Onoda N, Ito K, Suzuki S. Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan. J Nippon Med School. 2018;85:18\u201327.","journal-title":"J Nippon Med School"},{"key":"13217_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/hed.21721","volume":"34","author":"K Ito","year":"2012","unstructured":"Ito K, Hanamura T, Murayama K, Okada T, Watanabe T, Harada M, et al. Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors. Head Neck. 2012;34:230\u20137.","journal-title":"Head Neck"},{"key":"13217_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hed.24559","volume":"39","author":"S Baek","year":"2017","unstructured":"Baek S, Lee M, Hah JH, Ahn S, Son Y, Rho Y, et al. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012. Head Neck. 2017;39:133\u20139.","journal-title":"Head Neck"},{"key":"13217_CR26","doi-asserted-by":"publisher","first-page":"748023","DOI":"10.3389\/fendo.2021.748023","volume":"12","author":"W Zhou","year":"2021","unstructured":"Zhou W, Yue Y, Zhang X. Radiotherapy plus chemotherapy leads to prolonged survival in patients with anaplastic thyroid cancer compared with radiotherapy alone regardless of surgical resection and distant metastasis: a retrospective population study. Front Endocrinol. 2021;12:748023.","journal-title":"Front Endocrinol"},{"key":"13217_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3803\/EnM.2015.30.2.195","volume":"30","author":"TE Lo","year":"2015","unstructured":"Lo TE, Jimeno CA, Paz-Pacheco E. Anaplastic thyroid cancer: experience of the Philippine General Hospital. Endocrinol Metabolism. 2015;30:195\u2013200.","journal-title":"Endocrinol Metabolism"},{"key":"13217_CR28","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","volume":"36","author":"I Sugitani","year":"2012","unstructured":"Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients. World J Surg. 2012;36:1247\u201354.","journal-title":"World J Surg"},{"key":"13217_CR29","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.3390\/cancers13081913","volume":"13","author":"J Park","year":"2021","unstructured":"Park J, Park J, Shin JH, Oh Y-L, Jung H-A, Chung M-K, et al. Prognostic value of the neutrophil-to-lymphocyte ratio before and after radiotherapy for anaplastic thyroid carcinoma. Cancers. 2021;13:1913.","journal-title":"Cancers"},{"key":"13217_CR30","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.surg.2011.09.005","volume":"150","author":"Y Orita","year":"2011","unstructured":"Orita Y, Sugitani I, Amemiya T, Fujimoto Y. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery. 2011;150:1212\u20139.","journal-title":"Surgery"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13217-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13217-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:03:21Z","timestamp":1732878201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13217-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13217"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13217-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"2 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board (IRB) of the Faculty of Medicine at Ludwig-Maximilians-University Munich (Pettenkoferstr. 8a, 80336 Munich, Germany) reviewed and approved the retrospective study protocol (approval number: 20\u2013023). Informed consent was waived by the IRB due to the retrospective nature of the study and the analysis used only anonymous clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1477"}}